Management of antiretrovirals in seniors: the importance of assisted treatment for adherence to treatment

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

A semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescents

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

An exploration of adherence measures to detect recent changes in Truvada® dosing patterns

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Low isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Infant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Effect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Drugs abuse and chemsex: A new challenge for antiretroviral drug-drug interaction

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website.

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

The initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Population pharmacokinetics of VRC01 in infants and adults

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

In silico design of a microarray patch as a multipurpose prevention technology

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019

Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019